Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Perspective Therapeutics, Inc. (CATX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Perspective is a radiopharmaceutical development company focused on 212Pb-based theranostic treatments and imaging for cancer, and its filings offer detail on clinical progress, financial condition, and corporate governance.
Recent Form 8-K reports referenced in the input data include announcements of updated corporate presentations, interim clinical results from the Phase 1/2a trial of [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, and quarterly financial results with business highlights. Other 8-K filings describe executive leadership changes, such as the appointment of a new Chief Financial Officer and amended and restated employment agreements for senior executives, including change-in-control and severance terms.
Through this page, users can review Perspective’s current and historical 8-Ks and, when available, its periodic reports such as Forms 10-K and 10-Q, which typically contain audited or reviewed financial statements, segment information, and risk factor disclosures. These documents help clarify how the company funds its clinical programs, how it accounts for research and development and general and administrative expenses, and how it describes its radiopharmaceutical platform and manufacturing infrastructure enabled by its proprietary 212Pb generator.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify major clinical updates, financial trends, and governance changes. Real-time ingestion from EDGAR, along with structured access to items such as executive compensation arrangements and other material contracts, supports deeper analysis of CATX’s regulatory and corporate history.
Perspective Therapeutics, Inc. reported that it issued a press release on January 9, 2026 sharing updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET. This study involves patients with unresectable or metastatic neuroendocrine tumors that express somatostatin receptor subtype 2, a specific tumor marker. The updated data are being presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, held January 8–10, 2026 in San Francisco. Detailed clinical results are contained in the related press release, which is attached as an exhibit.
FMR LLCAbigail P. Johnson have filed an amended Schedule 13G reporting beneficial ownership of 312,164 shares of Perspective Therapeutics Inc. common stock, representing 0.4% of the outstanding class. FMR LLC has sole voting power over 303,643 shares and sole dispositive power over 312,164 shares, while Johnson is reported with sole dispositive power over the same 312,164 shares.
The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Perspective Therapeutics. It also notes that one or more other persons may have rights to dividends or sale proceeds from these shares, but no other individual interest exceeds five percent of the company’s common stock.
Perspective Therapeutics, Inc. reported that it updated its corporate presentation on December 1, 2025. The new version is being made available to the market as an exhibit to a current report, giving investors and other stakeholders refreshed information about the company’s business and strategy. The company’s common stock continues to trade on the NYSE American under the symbol CATX.
Perspective Therapeutics, Inc. (CATX)11/13/2025, the officer acquired 11,000 shares of common stock in an open market transaction coded “P” for purchase. The weighted average price paid was $2.0268 per share, with individual trades executed in a range from $2.0235 to $2.0300. Following this transaction, the officer beneficially owns 59,800 shares of Perspective Therapeutics common stock held directly.
Perspective Therapeutics (CATX) director Robert F. Williamson, III reported a Form 4 purchase of common stock. On 11/12/2025, he bought 9,498 shares (transaction code P) at $2.10 per share.
Following the transaction, the filing shows 9,864 shares held indirectly via the RFW3 Revocable Trust and 108,982 shares held directly. This reflects insider open-market buying and updates his reported holdings.
Perspective Therapeutics (CATX) reported Q3 2025 results showing continued investment in its radiopharmaceutical pipeline. The company recorded a net loss of $25.969 million (loss per share $0.35) on $209 thousand of grant revenue. Operating expenses were driven by R&D of $20.339 million and G&A of $7.731 million, resulting in an operating loss of $27.861 million.
Liquidity remains solid with $174.1 million in cash, cash equivalents and short‑term investments as of September 30, 2025, which the company believes will fund current plans into late 2026. Year‑to‑date, operating cash outflows were $57.827 million, partially offset by $12.691 million from investing activities and $10.318 million from financing, including $9.986 million raised via the at‑the‑market program in February 2025.
Common shares outstanding were 74,337,990 as of November 6, 2025. The company continues Phase 1/2a work across VMT‑α‑NET, VMT01 and PSV359 while building out manufacturing capacity to support clinical and future commercial supply.
Perspective Therapeutics (CATX) furnished a press release announcing its financial results for the quarter ended September 30, 2025, and provided recent business highlights. The company also posted an updated corporate presentation on its website.
The press release was furnished as Exhibit 99.1 under Item 2.02, and the corporate presentation was filed as Exhibit 99.2 under Item 8.01. The Item 2.02 information is expressly not deemed “filed” under Section 18 of the Exchange Act.
FMR LLCPerspective Therapeutics (CATX). The filing shows beneficial ownership of 6,063,330 shares of common stock, representing 8.2% of the class, with a date of event of 10/31/2025.
FMR reports sole voting power over 6,057,277 shares and sole dispositive power over 6,063,330 shares, with no shared voting or dispositive power. Abigail P. Johnson is also a reporting person with beneficial ownership of 6,063,330 shares (8.2%) via dispositive power.
The certification states the securities were acquired and are held in the ordinary course of business and not to change or influence control. The filing notes that one or more other persons may have rights to dividends or sale proceeds, and that no single such person has an interest exceeding 5% of the class.
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics (CATX) amended and restated employment agreements for its CEO Johan (Thijs) Spoor, Chief Accounting Officer Jonathan Hunt, and Chief Medical Officer Dr. Markus Puhlmann. The updates reflect current base salaries and revise change-in-control provisions.
Base salaries are $680,000 for Mr. Spoor, $451,500 for Mr. Hunt, and $516,700 for Dr. Puhlmann. If employment ends without cause or for good reason during the three months before or 12 months after a change in control, severance includes salary continuation for 12 months (18 months for Mr. Spoor), a pro‑rated target bonus, an additional amount equal to the target bonus (1.5x target for Mr. Spoor), and COBRA premiums for up to 12 months (18 months for Mr. Spoor).
Equity awards subject to time-based vesting accelerate to full vesting, and performance-based awards vest at target upon qualifying terminations in the protection period or if awards are not assumed, replaced, or continued at closing, subject to a release of claims. Other existing terms remain in effect.